Anzeige
Mehr »
Login
Dienstag, 22.04.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
Der Megatrend 2025: Die unterschätzte Chance im Uranmarkt - was diese Aktie JETZT interessant macht!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P72S | ISIN: NL0015285941 | Ticker-Symbol: 4A3
Tradegate
22.04.25
08:27 Uhr
3,634 Euro
-0,108
-2,89 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMATICS NV Chart 1 Jahr
5-Tage-Chart
IMMATICS NV 5-Tage-Chart
RealtimeGeldBriefZeit
3,6023,69208:52
3,6023,69208:52

Aktuelle News zur IMMATICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.04.Cantor Fitzgerald maintains overweight on Immatics stock52
27.03.Immatics GAAP EPS of €0.14 beats, revenue of $161.9M16
27.03.Immatics N.V. - 6-K, Report of foreign issuer6
IMMATICS Aktie jetzt für 0€ handeln
27.03.Immatics Announces Full Year 2024 Financial Results and Business Update350Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203...
► Artikel lesen
27.03.Immatics N.V. - 20-F, Annual and transition report of foreign private issuers4
13.01.Immatics N.V. - 6-K, Report of foreign issuer49
17.12.24Bristol Myers Squibb und der große Hoffnungsträger - Immatics-Deal vor dem Aus1.499Vor knapp einem Jahr sorgte Bristol Myers Squibb mit einem Übernahme-Doppelschlag für Furore. Um Weihnachten herum kündigten die Amerikaner die Akquisitionen von Karuna Therapeutics und RayzeBio an....
► Artikel lesen
16.12.24BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Century, Immatics22
13.12.24Immatics N.V. - 6-K, Report of foreign issuer13
20.11.24Immatics: Deutsche Biotech-Hoffnung unter Druck1.246Trotz vielversprechender Studiendaten befindet sich der Biotech-Hot-Stock Immatics sei einigen Wochen auf dem absteigenden Ast. Vor allem das Timing einer Kapitalmaßnahme ist einigen Marktteilnehmern...
► Artikel lesen
18.11.24Immatics GAAP EPS of -€0.11, revenue of €50.56M10
18.11.24Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER IMA402 Targeting PRAME374The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical...
► Artikel lesen
18.11.24Immatics N.V. - 6-K, Report of foreign issuer1
08.11.24Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME635Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics' TCR-T PRAME franchise to target solid cancers ACTengine®...
► Artikel lesen
08.11.24Immatics N.V. - 6-K, Report of foreign issuer9
11.10.24Immatics Announces Pricing of $150 Million Public Offering824Houston, Texas and Tuebingen, Germany, October 10, 2024 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting...
► Artikel lesen
10.10.24Immatics Announces Proposed $150 Million Public Offering660Houston, Texas and Tuebingen, Germany, October 10, 2024 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting...
► Artikel lesen
10.10.24Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial431Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated...
► Artikel lesen
04.10.24Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024282Houston, Texas and Tuebingen, Germany, October 4, 2024 - Immatics N.V.(NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development...
► Artikel lesen
16.09.24Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update474TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on...
► Artikel lesen
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2